Evaxion reported characterization results for EVX-04, an AI-designed DNA vaccine encoding antigenic fragments derived from 1β endogenous retroviruses. The goal is to drive broad antigen-specific T-cell responses targeting acute myeloid leukemia (AML) blasts expressing ERV antigens. The update emphasizes the vaccine design concept—using AI to identify antigenic features from ERV-derived sequences—and frames EVX-04 as part of the company’s immunotherapy pipeline for AML. For the field, ERV-directed approaches seek to widen the pool of tumor antigens while enabling more uniform immune targeting across genetically diverse patients, though efficacy will depend on how the immune response translates in ongoing development.